van der Zee HH, et al. - In moderate-to-severe hidradenitis suppurativa (HS; a chronic skin disease characterized by inflammatory lesions that flare unpredictably) patients, researchers assessed the impact of disease flare on health-related quality of life (HRQOL) and determined the impact of weekly adalimumab (ADAew) on disease flare using integrated data from two phase 3 trials over 36 weeks. Among those who did not experience flare, HRQOL was markedly improved. The reduction of flare is an important HS measure that correlates with HRQOL's clinically meaningful improvement. Through 12 and subsequent 36 weeks of treatment, ADAew reduces HS flare.